Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR…
Latest News
-
-
Corxel to advance oral obesity drug to Phase III trials
Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a…
-
US launches Operation Trailblazer to strengthen clinical trials
The US Department of Health and Human Services (HHS) has announced a coordinated department-wide effort to strengthen America’s leadership in…
-
Analysts point to Definium psychedelic’s MDD efficacy on Phase III success
Following the first late-stage win in a Phase III programme evaluating Definium Therapeutics’ lysergic acid diethylamide (LSD)-based psychedelic in major…
-
MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial
MSD’s investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), which it acquired during a $10.8bn buyout of…
-
Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
-
HLTH Europe 2026: incorporating RWE into practice – the perks and pitfalls
As the life sciences sector rapidly progresses into the digital age, several tools are emerging with the potential to revolutionise…
-
Verastem Oncology’s pancreatic cancer combo shows 86% OS rate
Verastem Oncology’s pancreatic cancer combination has shown an 86% overall survival (OS) rate in a Phase Ib/IIa trial. In the…
-
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate.…
-
Lilly’s JAK2 inhibitor from $2.3bn acquisition shows early promise
Eli Lilly’s type II JAK2 inhibitor, which it acquired through the $2.3bn acquisition of Ajax Therapeutics earlier this year, has…
